ADMA - Why ADMA Biologics iBio and Kamada Are Jumping Today
At a news conference Sunday, President Donald Trump announced that the Food and Drug Administration issued an emergency use authorization (EUA) for convalescent plasma therapy as a treatment for hospitalized COVID-19 patients. Convalescent plasma is the liquid component of blood containing antibodies from patients previously infected with the virus.
In response to this news, shares of the convalescent plasma therapy players ADMA Biologics (NASDAQ: ADMA), iBio (NYSEMKT: IBIO), and Kamada (NASDAQ: KMDA) each got a nice boost in pre-market trading Monday morning. ADMA Biologics' stock jumped by a healthy 68%, iBio's shares rose by a handsome 28%, and Kamada's equity perked up as much as 24% in early morning action today.
Image source: Getty Images.